← Back to Search

Nonsteroidal Anti-inflammatory Drug (NSAID)

Cambia for Migraine

Phase 4
Waitlist Available
Led By Emily Rubenstein Engel, MD
Research Sponsored by Scripps Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention
Awards & highlights
Pivotal Trial
All Individual Drugs Already Approved
Drug Has Already Been Approved
Approved for 5 Other Conditions

Summary

This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.

Eligible Conditions
  • Migraine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5, 10, 15, 30, 60, 120 minutes and 24 hours post intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in severity of migraine associated symptoms
Return to function

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CambiaExperimental Treatment1 Intervention
Diclofenac postassium powder for oral solution and placebo injection
Group II: ketorolacActive Control1 Intervention
ketorolac intramuscular injection and placebo oral solution

Find a Location

Who is running the clinical trial?

Scripps HealthLead Sponsor
58 Previous Clinical Trials
43,533 Total Patients Enrolled
1 Trials studying Migraine
60 Patients Enrolled for Migraine
DepomedIndustry Sponsor
20 Previous Clinical Trials
3,540 Total Patients Enrolled
1 Trials studying Migraine
25 Patients Enrolled for Migraine
Emily Rubenstein Engel, MDPrincipal InvestigatorScripps Health
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top